trial

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

NCTId NCT02832037
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 509 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2019-12-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
509 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-07-25
Primary completion
2019-12-27
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
BI 425809 dose 1BI 425809 dose 2BI 425809 dose 3BI 425809 dose 4

Sponsors

Boehringer IngelheimLead Sponsor

Sites

81 total
Garden Grove, United StatesLemon Grove, United StatesOrange, United StatesPanorama City, United StatesPico Rivera, United StatesSan Diego, United StatesMiami, United StatesAtlanta, United StatesAtlanta, United StatesChicago, United StatesLake Charles, United StatesAnn Arbor, United States

Linked catalysts

1
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schiz — primary completion2019-12-27

Facts & assertions

4 sourced
Enrollment
509
Phase
PHASE2
Primary Completion Date
2019-12-27
Status
COMPLETED
relationships
The graph out of here
drug
BI 425809 dose 1
drug
BI 425809 dose 2
drug
BI 425809 dose 3
drug
BI 425809 dose 4
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication